Corporate
2021.11.16
LT1001 Formulation Patent Granted by JPO
Corporate
2021.09.16
Lumosa Therapeutics Announces FDA Clearance of IND Application Its LT3001, a New Drug for the Treatment of Acute Ischemic Stroke, for Multi-dose Phase 2 Trial in Combination with Mechanical Thrombectomy
Corporate
2021.09.05
Lumosa CEO's Interview by Kevin Price on the Price of Business Show
Corporate
2021.08.03
Lumosa Therapeutics Announces Positive Result from LT3001 Phase 2A Clinical Trial in Acute Ischemic Stroke
LT3001 represents a completely novel drug design in stroke treatment -- combining thrombolytic and neuroprotective properties into a single molecule which may confer unique efficacy and safety properties permitting a brand new perspective to the AIS patients.
Corporate
2021.06.23
Lumosa and DONGWHA Enter Exclusive Distributorship Agreement for LT1001 in Korea – Securing a Foot in Northeast Asia and Increase Global Licensing Value
Corporate
2021.06.16
Formulation Patent for LT1001, An Extended-Release Analgesic Injection, Granted by Chinese Patent Office